Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 20/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14739613 | 0.95 | KIT (0.71) | KIT | |
| SCHEMBL27338941 | 0.93 | KIT (0.67) | KIT | |
| SCHEMBL21387340 | 0.93 | KIT (0.67) | KIT | |
| SCHEMBL21372445 | 0.93 | KIT (0.78) | KIT | |
| SCHEMBL14739909 | 0.92 | KIT (0.78) | KIT | |
| SCHEMBL14755315 | 0.92 | KIT (0.66) | KIT | |
| SCHEMBL14739838 | 0.92 | KIT (0.66) | KIT | |
| SCHEMBL27336728 | 0.91 | KIT (0.65) | KIT | |
| SCHEMBL14739329 | 0.91 | KIT (0.82) | KIT | |
| SCHEMBL14740384 | 0.90 | KIT (0.65) | KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2751104-B1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | NOVARTIS AG (CH) | 2019-09-25 | — | — | EP | claimed |
| US-9023839-B2 | Compounds and compositions as c-kit kinase inhibitors | IRM LLC (BM) | 2015-05-05 | — | — | US | claimed |
| US-20140228347-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2014-08-14 | — | — | US | claimed |
| EP-2751104-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2014-07-09 | — | — | EP | claimed |
| US-8754071-B2 | Compounds and compositions as c-kit kinase inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2014-06-17 | — | — | US | claimed |
| US-20140031333-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2014-01-30 | — | — | US | claimed |
| US-8569283-B2 | Compounds and compositions as c-Kit kinase inhibitors | IRM LLC (BM) | 2013-10-29 | — | — | US | claimed |
| WO-2013033167-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | WO | claimed |
| US-20130059832-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | US | claimed |
| EP-2751104-B1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | NOVARTIS AG (CH) | 2019-09-25 | — | — | EP | disclosed |
| EP-2751104-B1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | NOVARTIS AG (CH) | 2019-09-25 | — | — | EP | disclosed |
| US-9023839-B2 | Compounds and compositions as c-kit kinase inhibitors | IRM LLC (BM) | 2015-05-05 | — | — | US | disclosed |
| US-9023839-B2 | Compounds and compositions as c-kit kinase inhibitors | IRM LLC (BM) | 2015-05-05 | — | — | US | disclosed |
| US-9023839-B2 | Compounds and compositions as c-kit kinase inhibitors | IRM LLC (BM) | 2015-05-05 | — | — | US | disclosed |
| US-8569283-B2 | Compounds and compositions as c-Kit kinase inhibitors | IRM LLC (BM) | 2013-10-29 | — | — | US | disclosed |
| WO-2013033167-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059832-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | US | disclosed |
| US-20130059832-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | US | disclosed |
| US-20130059832-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | US | disclosed |
| WO-2013033167-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031333-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | KIT, PDGFRA, PDGFRB | KIT 1/4885 |
| US-20130059832-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | KIT, PDGFRA, PDGFRB | KIT 1/4885 |
| US-20140228347-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | KIT, PDGFRA, PDGFRB | KIT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.